In this report activation of CD27 was triggered by Ipili + vaccine immunotherapy in prostate cancer pts. CDX-1127 is being tested as an activator of CD27 in solid tumors. CLDX has indicated that they will use 1127 both as monotherapy and in combination with other therapies. There is still a lot of work to be done, but it appears that CLDX is on the right track with CDX-1127:
Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity.
Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;
The interaction between CD27 and its ligand, CD70, has been implicated in regulating cellular immune responses to cancer. In this article, we report on the role of soluble CD27 (sCD27) in T cell activation and its elevation in the serum of cancer patients after immunotherapy. In vitro, sCD27 is preferentially derived from activated CD4(+) T cells. Adding sCD27 to stimulated PBMCs increases T cell activation and proliferation, and is associated with the immunologic synapse-related proteins myosin IIA, high mobility group box 1, and the TCR Vβ-chain. The pool of serum sCD27 is shown to be greater in healthy donors than in cancer patients. However, metastatic cancer patients treated with immunotherapy showed a significant increase in the serum sCD27-pool posttherapy (p
Sentiment: Strong Buy